$BRST
Broad Street Realty, Inc.

2018 Q3 Form 10-Q Financial Statement

#000143774918014411 Filed on August 03, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $133.4K $90.00K $110.0K
YoY Change -48.69% -18.18% -21.43%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $808.00 $808.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $133.4K $90.00K $110.0K
YoY Change -48.69% -18.18% -21.43%
Operating Profit -$133.4K -$86.74K -$114.1K
YoY Change -48.98% -24.0% -17.58%
Interest Expense $256.00 $384.00 $3.110K
YoY Change -79.19% -87.65%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$133.7K -$90.00K -$120.0K
YoY Change -48.59% -25.0% -14.29%
Income Tax
% Of Pretax Income
Net Earnings -$133.7K -$87.13K -$117.3K
YoY Change -49.12% -25.69% -15.34%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$51.20K -$34.48K -$113.2K
COMMON SHARES
Basic Shares Outstanding 2.611M 10.57M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $262.4K $360.0K $1.320M
YoY Change -77.19% -72.73% 2100.0%
Cash & Equivalents $262.4K $357.9K $1.324M
Short-Term Investments
Other Short-Term Assets $45.89K $20.00K $10.00K
YoY Change 52.97% 100.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $308.2K $376.1K $1.340M
YoY Change -73.81% -71.93% 1770.1%
LONG-TERM ASSETS
Property, Plant & Equipment $19.38K $20.19K
YoY Change -14.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $19.38K $54.81K
YoY Change -14.67%
TOTAL ASSETS
Total Short-Term Assets $308.2K $376.1K $1.340M
Total Long-Term Assets $19.38K $54.81K
Total Assets $327.6K $430.9K $1.340M
YoY Change -72.69% -67.84% 1770.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $43.06K $50.00K $150.0K
YoY Change -79.5% -66.67% 100.41%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $45.67K $10.00K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $116.1K $85.70K $180.0K
YoY Change -50.37% -52.39% -51.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $116.1K $85.70K $180.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $116.1K $85.70K $180.0K
YoY Change -50.37% -52.39% -51.94%
SHAREHOLDERS EQUITY
Retained Earnings -$111.7M -$111.5M $0.00
YoY Change 0.69% -100.0%
Common Stock $26.11K $26.11K $158.5K
YoY Change 36.89% -83.53% 53.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change -100.0%
Treasury Stock Shares
Shareholders Equity $211.5K $345.2K $1.159M
YoY Change
Total Liabilities & Shareholders Equity $327.6K $430.9K $1.338M
YoY Change -72.69% -67.8% 1767.78%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$133.7K -$87.13K -$117.3K
YoY Change -49.12% -25.69% -15.34%
Depreciation, Depletion And Amortization $808.00 $808.00 $0.00
YoY Change
Cash From Operating Activities -$82.83K -$110.0K -$90.00K
YoY Change -81.99% 22.22% -25.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.190K -20.00K 750.0K
YoY Change -100.97% -102.67%
NET CHANGE
Cash From Operating Activities -82.83K -110.0K -90.00K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -3.190K -20.00K 750.0K
Net Change In Cash -86.02K -130.0K 660.0K
YoY Change -52.21% -119.7% -650.0%
FREE CASH FLOW
Cash From Operating Activities -$82.83K -$110.0K -$90.00K
Capital Expenditures $0.00
Free Cash Flow -$82.83K
YoY Change -81.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Registrant Name
EntityRegistrantName
MedAmerica Properties Inc.
mamp Decrease In Accrued Interest Related Party
DecreaseInAccruedInterestRelatedParty
mamp Decrease In Accrued Interest Related Party
DecreaseInAccruedInterestRelatedParty
13208
mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
295542
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000764897
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
dei Trading Symbol
TradingSymbol
mamp
dei Document Type
DocumentType
10-Q
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2610568
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
106870
CY2018Q2 mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
86741
CY2017Q2 mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
114140
CY2018Q2 mamp Net Working Capital
NetWorkingCapital
290000
mamp Percentage Of Income Tax Examination Likelihood Of Tax Benefits Being Realized Upon Settlement
PercentageOfIncomeTaxExaminationLikelihoodOfTaxBenefitsBeingRealizedUponSettlement
0.5
CY2018Q2 mamp Preferred Stock Amount Of Preferred Dividends Undeclared And Unaccrued
PreferredStockAmountOfPreferredDividendsUndeclaredAndUnaccrued
7500
CY2017 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
0
CY2018Q1 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
0
CY2018Q2 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
CY2017 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
0
CY2018Q1 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
CY2018Q2 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
mamp Preferred Stock Dividend In Excess Of Payments
PreferredStockDividendInExcessOfPayments
mamp Preferred Stock Dividend In Excess Of Payments
PreferredStockDividendInExcessOfPayments
25945
mamp Proceeds From Common Stock Subscribed Net Of Expenses
ProceedsFromCommonStockSubscribedNetOfExpenses
mamp Proceeds From Common Stock Subscribed Net Of Expenses
ProceedsFromCommonStockSubscribedNetOfExpenses
1733928
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q1 mamp Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
CY2018Q2 mamp Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P5Y
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
50147
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
66319
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2424
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111861799
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111861799
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10375
CY2018Q2 us-gaap Assets
Assets
430899
CY2017Q4 us-gaap Assets
Assets
768381
CY2018Q2 us-gaap Assets Current
AssetsCurrent
376093
CY2017Q4 us-gaap Assets Current
AssetsCurrent
746573
CY2018Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
54806
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21808
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Principles of Consolidation and Basis of Presentation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany account balances have been eliminated in consolidation. The accompanying Financial Statements give effect to all adjustments necessary to present fairly the financial position and results of operations and cash flows of the Company and its subsidiaries.</div></div>
CY2018Q2 us-gaap Cash
Cash
358000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
708382
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
450
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
357903
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1324110
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-350479
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1323660
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
60000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2610568
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2610568
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
26105
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
26105
CY2017Q3 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
148125
us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
0
us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
148125
CY2018Q2 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
0
CY2017Q2 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
148125
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
110000
CY2018Q2 us-gaap Depreciation
Depreciation
808
us-gaap Depreciation
Depreciation
1616
us-gaap Depreciation
Depreciation
CY2018Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
27361
CY2017Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
27361
CY2018Q2 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
34614
CY2017Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5650
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16171
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
56345
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
34614
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-20000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17471
us-gaap Interest Expense
InterestExpense
768
us-gaap Interest Expense
InterestExpense
15388
CY2018Q2 us-gaap Interest Expense
InterestExpense
384
CY2017Q2 us-gaap Interest Expense
InterestExpense
3110
us-gaap Interest Paid Net
InterestPaidNet
768
us-gaap Interest Paid Net
InterestPaidNet
15388
CY2018Q2 us-gaap Liabilities
Liabilities
85699
CY2017Q4 us-gaap Liabilities
Liabilities
126871
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
430899
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768381
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
85699
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126871
CY2018Q2 us-gaap Loans Payable Current
LoansPayableCurrent
8191
CY2017Q4 us-gaap Loans Payable Current
LoansPayableCurrent
33191
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Nature of Operations</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:42.9pt;">MedAmerica Properties Inc. (the &#x201c;Company&#x201d; or &#x201c;MedAmerica&#x201d;), was originally organized under the laws of the Commonwealth of Massachusetts in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1985,</div> under the name VMS Hotel Investment Trust, for the purpose of investing in mortgage loans. The Company was subsequently reorganized as a Delaware corporation in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1987</div> and changed its name to B.H.I.T. Inc. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> the Company changed its name from B.H.I.T. Inc. to Banyan Rail Services Inc. From <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> the Company experienced severe losses from an operating subsidiary in the rail services sector. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> after exploring various industries and researching numerous companies, the board of directors elected to pursue investing in commercial real estate. The Company is pursuing the acquisition and management of strategically located medical office buildings.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3.3pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:38.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>our board of directors and the holders of a majority of our outstanding shares of common stock approved by written consent amendments to the Company&#x2019;s certificate of incorporation to (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) change the name of the Company from &#x201c;Banyan Rail Services Inc.&#x201d; to &#x201c;MedAmerica Properties Inc.,&#x201d; and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) effect a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> reverse stock split of the issued and outstanding shares of common stock of the Company. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 15, 2017, </div>the Company filed these amendments with the Secretary of State of the State of Delaware and the name change and reverse stock split became effective with the Financial Industry Regulatory Authority, Inc. (&#x201c;FINRA&#x201d;) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 20, 2017. </div>As appropriate, all common stock share quantities have been updated to reflect the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> reverse stock split.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1275310
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-325479
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61650
us-gaap Net Income Loss
NetIncomeLoss
-296310
us-gaap Net Income Loss
NetIncomeLoss
-122258
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-87125
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-117250
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-298810
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-272883
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88375
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-266625
us-gaap Operating Income Loss
OperatingIncomeLoss
-295542
us-gaap Operating Income Loss
OperatingIncomeLoss
-106870
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-86741
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-114140
CY2017 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
27361
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
27361
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.1
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2500
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2500
CY2018Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1250
CY2017Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1250
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2018Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
18190
CY2017Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
38191
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1940005
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1940005
us-gaap Proceeds From Mortgage Deposits
ProceedsFromMortgageDeposits
us-gaap Proceeds From Mortgage Deposits
ProceedsFromMortgageDeposits
110000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
169138
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22616
us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Equipment and Furnishings</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.7pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">Equipment and furnishings are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div> years. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in income for the period statement of operations.</div></div></div></div></div></div></div></div></div>
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20192
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21808
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
627756
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111542709
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111246399
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
60000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
60000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.71
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
60000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
70000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y182D
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y131D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
70000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
345200
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
641510
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">The preparation of financial statements, in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"), requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and disclosures of contingent assets and liabilities at the date and period ending of the financial statements. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1056724
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1056724

Files In Submission

Name View Source Status
0001437749-18-014411-index-headers.html Edgar Link pending
0001437749-18-014411-index.html Edgar Link pending
0001437749-18-014411.txt Edgar Link pending
0001437749-18-014411-xbrl.zip Edgar Link pending
ex_118801.htm Edgar Link pending
ex_118802.htm Edgar Link pending
ex_118803.htm Edgar Link pending
ex_118804.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mamp-20180630.xml Edgar Link completed
mamp-20180630.xsd Edgar Link pending
mamp-20180630_cal.xml Edgar Link unprocessable
mamp-20180630_def.xml Edgar Link unprocessable
mamp-20180630_lab.xml Edgar Link unprocessable
mamp-20180630_pre.xml Edgar Link unprocessable
mamp20180630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending